Hepatic Injury – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Hepatic Injury – Drugs In Development, 2024 report and make more profitable business decisions.
Hepatic injury, or liver trauma/injury, can occur from both penetrating and blunt abdominal injuries, including falls. The liver is the most injured organ in the human body. Liver traumas can range from minor lacerations or capsular hematomas to severe liver injuries with a high mortality rate. The frequency of liver injury could be due to its relatively fragile parenchyma and its fixed location below the diaphragm making it vulnerable to trauma. Diagnosis is done by physical and laboratory examination, or by administering IV contrast with CT scan to identify the extravasation of blood. Treatment is operative or nonoperative. Non-operative is chosen in hemodynamically stable patients, while the hemodynamically unstable are treated surgically.
The Hepatic Injury drugs in development market research report provide comprehensive information on the therapeutics under development for Hepatic Injury, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Hepatic Injury and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Hepatic Injury | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 13 molecules, with 11 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Hepatic Injury therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Hepatic Injury pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Hepatic Injury treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
Chonbuk National University School of MedicineElicio Therapeutics Inc
Guizhou Medical University Hospital
iRegene Therapeutics Co Ltd
Kyoto Pharmaceutical University
Lydex Pharmaceuticals LLC
Mallinckrodt Plc
Mitotherapeutix LLC
Principia Biopharma Inc
Ractigen Therapeutics Inc
Vaxil Bio Therapeutics Ltd
Worphmed Srl
Xfibra Inc
Table of Contents
Table
Figures
Frequently asked questions
Related reports
View more Hepatic Injury reports